Adverse effects of androgen deprivation therapy and strategies to mitigate them

European Urology

Volumn 67, Issue 5, 2015, Pages 825-836

  Nguyen, Paul L ^a   Alibhai, Shabbir M H ^b   Basaria, Shehzad ^c   D'Amico, Anthony V ^a   Kantoff, Philip W ^c   Keating, Nancy L ^c   Penson, David F ^d   Rosario, Derek J ^e   Tombal, Bertrand ^f   Smith, Matthew R ^g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Androgen deprivation therapy; Prostate cancer

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; DENOSUMAB; ESTROGEN RECEPTOR; GABAPENTIN; MEDROXYPROGESTERONE; TAMOXIFEN; VENLAFAXINE;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; INSULIN RESISTANCE; LIBIDO DISORDER; MEDICARE; MEDLINE; METABOLIC SYNDROME X; MUSCLE MASS; OBSERVATIONAL STUDY; OSTEOLYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SEXUAL DYSFUNCTION; WEIGHT GAIN;

EID: 84964308904     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.07.010     Document Type: Review

References (109)

1. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
2. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
3. J.W. Denham, A. Steigler, and D.S. Lamb Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
4. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
5. C.A. Lawton, K. Winter, and D. Grignon Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31 J Clin Oncol 23 2005 800 807
6. E.M. Messing, J. Manola, and M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
7. J.F. Maillefert, J. Sibilia, and F. Michel Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma J Urol 161 1999 1219 1222
8. A. Berruti, L. Dogliotti, and C. Terrone Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy J Urol 167 2002 2361 2367
9. D. Goldray, Y. Weisman, and N. Jaccard Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH) J Clin Endocrinol Metab 76 1993 288 290
10. H.W. Daniell, S.R. Dunn, and D.W. Ferguson Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 2000 181 186
11. M.R. Smith, W.C. Lee, and J. Brandman Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 2005 7897 7903
12. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
13. M. Datta, and G.G. Schwartz Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review Oncologist 17 2012 1171 1179
14. Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation Web site. http://www.nof.org/files/nof/public/content/file/344/upload/159.pdf.
15. M.R. Smith, F.J. McGovern, and A.L. Zietman Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 2001 948 955
16. R. Choo, H. Lukka, and P. Cheung Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy Int J Radiat Oncol Biol Phys 85 2013 1239 1245
17. M.R. Smith, J. Eastham, and D.M. Gleason Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
18. S.L. Greenspan, J.B. Nelson, and D.L. Trump Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann Intern Med 146 2007 416 424
19. L.H. Klotz, I.Y. McNeill, and M. Kebabdjian A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study Eur Urol 63 2013 927 935
20. A. Serpa Neto, M. Tobias-Machado, and M.A. Esteves Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis Prostate Cancer Prostatic Dis 15 2012 36 44
21. M.R. Smith, B. Egerdie, and N. Hernandez Toriz Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
22. M.R. Smith, M.A. Fallon, and H. Lee Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 89 2004 3841 3846
23. M.R. Smith, R.A. Morton, and K.G. Barnette Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer J Urol 184 2010 1316 1321
24. M.R. Smith, M. Goode, and A.L. Zietman Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition J Clin Oncol 22 2004 2546 2553
25. P.R. Sieber, D.L. Keiller, and R.J. Kahnoski Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer J Urol 171 2004 2272 2276 quiz 2435
26. J. Seidenfeld, D.J. Samson, and V. Hasselblad Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 2000 566 577
27. J.R. Gralow, J.S. Biermann, and A. Farooki NCCN Task Force Report: Bone Health in Cancer Care J Natl Compr Canc Netw 11 Suppl 3 2013 S1 S50
28. J.L. Mohler, A.J. Armstrong, and R.R. Bahnson Prostate cancer, version 3.2012: featured updates to the NCCN guidelines J Natl Compr Canc Netw 10 2012 1081 1087
29. M.R. Smith, J.S. Finkelstein, and F.J. McGovern Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599 603
30. M.R. Smith, H. Lee, and D.M. Nathan Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 2006 1305 1308
31. S. Basaria, D.C. Muller, and M.A. Carducci Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy Cancer 106 2006 581 588
32. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
33. N.L. Keating, A.J. O'Malley, and S.J. Freedland Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
34. N.L. Keating, A. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. [published correction appears in J Natl Cancer Inst 2012; 104: 1518-23] J Natl Cancer Inst 102 2010 39 46
35. S.M. Alibhai, M. Duong-Hua, and R. Sutradhar Impact of androgen deprivation therapy on cardiovascular disease and diabetes J Clin Oncol 27 2009 3452 3458
36. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel, III) JAMA 285 2001 2486 2497
37. J.C. Smith, S. Bennett, and L.M. Evans The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer J Clin Endocrinol Metab 86 2001 4261 4267
38. M. Braga-Basaria, A.S. Dobs, and D.C. Muller Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 24 2006 3979 3983
39. J.P. Nobes, S.E. Langley, and T. Klopper A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy BJU Int 109 2012 1495 1502
40. R.J. Segal, R.D. Reid, and K.S. Courneya Resistance exercise in men receiving androgen deprivation therapy for prostate cancer J Clin Oncol 21 2003 1653 1659
41. D. Santa Mina, S.M.H. Alibhai, and A.G. Matthew A randomized trial of aerobic versus resistance exercise in prostate cancer survivors J Aging Phys Act 21 2013 455 478
42. C.L. Carmack Taylor, C. Demoor, and M.A. Smith Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients Psychooncology 15 2006 847 862
43. D.A. Galvao, N. Spry, and D.R. Taaffe A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial BMC Cancer 9 2009 419
44. R.U. Newton, D.R. Taaffe, and N. Spry Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation? BMC Cancer 12 2012 432
45. American Diabetes, Association. Standards of medical care in, diabetes - 2013 Diabetes Care 36 Suppl 1 2013 S11 S66
46. N.L. Keating, P.-H. Liu, and A.J. O'Malley Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer Eur Urol 65 2014 816 824
47. N.J. Stone, J. Robinson, and A.H. Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 Suppl 2 2014 S1 S45
48. H.K. Tsai, A.V. D'Amico, and N. Sadetsky Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516 1524
49. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
50. G.N. Levine, A.V. D'Amico, and P. Berger Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Circulation 121 2010 833 840
51. FDA drug safety communication: Update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm. Accessed August 17, 2011.
52. L. Azoulay, H. Yin, and S. Benayoun Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer Eur Urol 60 2011 1244 1250
53. J.C. Hu, S.B. Williams, and A.J. O'Malley Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism Eur Urol 61 2012 1119 1128
54. M. Van Hemelrijck, H. Garmo, and L. Holmberg Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden J Clin Oncol 28 2010 3448 3456
55. C.G. Jespersen, M. Norgaard, and M. Borre Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study Eur Urol 65 2014 704 709
56. S. Punnen, M.R. Cooperberg, and N. Sadetsky Androgen deprivation therapy and cardiovascular risk J Clin Oncol 29 2011 3510 3516
57. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99
58. M. Roach III, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
59. C. Wilcox, A. Kautto, and A. Steigler Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term Oncology 82 2012 56 58
60. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02 Eur Urol 54 2008 816 824
61. P.L. Nguyen, Y. Je, and F.A. Schutz Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials JAMA 306 2011 2359 2366
62. L. Bourke, P. Kirkbride, R. Hooper, A.J. Rosario, T.J. Chico, and D.J. Rosario Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer 108 2013 9 13
63. J.F. Piccirillo, R.M. Tierney, and I. Costas Prognostic importance of comorbidity in a hospital-based cancer registry JAMA 291 2004 2441 2447
64. A. Nanda, M.H. Chen, and M.H. Braccioforte Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
65. P.L. Nguyen, M.H. Chen, and J.A. Beckman Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction Int J Radiat Oncol Biol Phys 82 2012 1411 1416
66. N.L. Keating, A.J. O'Malley, and S.J. Freedland Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64 2013 159 166
67. M.R. Smith, L. Klotz, and B.E. Persson Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer J Urol 184 2010 2313 2319
68. M.R. Smith, L. Klotz, and E. van der Meulen Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix J Urol 186 2011 1835 1842
69. P.C. Albertsen, L. Klotz, and B. Tombal Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist Eur Urol 65 2014 565 573
70. S. Basaria, J. Lieb II, and A.M. Tang Long-term effects of androgen deprivation therapy in prostate cancer patients Clin Endocrinol (Oxf) 56 2002 779 786
71. C.S. Higano Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer J Clin Oncol 30 2012 3720 3725
72. R.M. Hoffman, W.C. Hunt, and F.D. Gilliland Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study Cancer 97 2003 1653 1662
73. J.M. Crook, C.J. O'Callaghan, and G. Duncan Intermittent androgen suppression for rising PSA level after radiotherapy N Engl J Med 367 2012 895 903
74. M. Hussain, C.M. Tangen, and D.L. Berry Intermittent versus continuous androgen deprivation in prostate cancer N Engl J Med 368 2013 1314 1325
75. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
76. J.W. Denham, C. Wilcox, and D. Joseph Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial Lancet Oncol 13 2012 1260 1270
77. P. Cormie, R.U. Newton, and D.R. Taaffe Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial Prostate Cancer Prostatic Dis 16 2013 170 175
78. C.J. Tyrrell, H. Payne, and T.L. Tammela Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia Int J Radiat Oncol Biol Phys 60 2004 476 483
79. G. Di Lorenzo, R. Autorino, and S. Perdona Management of gynaecomastia in patients with prostate cancer: a systematic review Lancet Oncol 6 2005 972 979
80. A. Widmark, S.D. Fossa, and P. Lundmo Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3 Urology 61 2003 145 151
81. F. Boccardo, A. Rubagotti, and M. Battaglia Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer J Clin Oncol 23 2005 808 815
82. G. Di Lorenzo, S. Perdona, and S. De Placido Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy J Urol 174 2005 2197 2203
83. S. Perdona, R. Autorino, and S. De Placido Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial Lancet Oncol 6 2005 295 300
84. F. Hadziselimovic, E. Senn, and K. Bandhauer Effect of treatment with chronic gonadotropin releasing hormone agonist on human testis J Urol 138 1987 1048 1050
85. A. Haliloglu, S. Baltaci, and O. Yaman Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer J Urol 177 2007 128 130
86. A. Parekh, M.H. Chen, and K.E. Hoffman Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone Urology 81 2013 130 134
87. F.T. Baumann, E.M. Zopf, and W. Bloch Clinical exercise interventions in prostate cancer patients - a systematic review of randomized controlled trials Support Care Cancer 20 2012 221 233
88. D.A. Galvão, D.R. Taaffe, and N. Spry Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial J Clin Oncol 28 2010 340 347
89. L. Bourke, S. Gilbert, and R. Hooper Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial Eur Urol 65 2014 865 872
90. S.N. Culos-Reed, J.W. Robinson, and H. Lau Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention Support Care Cancer 18 2010 591 599
91. F. Haseen, L.J. Murray, and R.F. O'Neill A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy Trials 11 2010 86
92. C.L. Loprinzi, A.C. Dueck, and B.S. Khoyratty A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB) Ann Oncol 20 2009 542 549
93. J. Irani, L. Salomon, and R. Oba Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial Lancet Oncol 11 2010 147 154
94. P. Sharma, A. Wisniewski, and M. Braga-Basaria Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy J Urol 182 2009 2265 2272
95. M.Z. Vitolins, L. Griffin, and W.V. Tomlinson Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer J Clin Oncol 31 2013 4092 4098
96. M.S. Lee, K.H. Kim, and B.C. Shin Acupuncture for treating hot flushes in men with prostate cancer: a systematic review Support Care Cancer 17 2009 763 770
97. C. Harding, A. Harris, and D. Chadwick Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer BJU Int 103 2009 186 190
98. H. Ashamalla, M.L. Jiang, and A. Guirguis Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy Int J Radiat Oncol Biol Phys 79 2011 1358 1363
99. S.D. Moffat, A.B. Zonderman, and E.J. Metter Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men J Clin Endocrinol Metab 87 2002 5001 5007
100. H.J. Green, K.I. Pakenham, and B.C. Headley Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial BJU Int 90 2002 427 432
101. S.M. Alibhai, H. Breunis, and N. Timilshina Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer J Clin Oncol 28 2010 5030 5037
102. C.E. Lee, A. Kilgour, and Y.K. Lau Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy BMC Cancer 12 2012 324
103. M. Grossmann, and J.D. Zajac Hematological changes during androgen deprivation therapy Asian J Androl 14 2012 187 192
104. R. Fonseca, S.V. Rajkumar, and W.L. White Anemia after orchiectomy Am J Hematol 59 1998 230 233
105. A.V. D'Amico, T. Saegaert, and M.H. Chen Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer Cancer 95 2002 275 280
106. N. Timilshina, S. Hussain, and H. Breunis Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study Support Care Cancer 19 2011 1815 1821
107. T.M. Beer, C.M. Tangen, and L.B. Bland The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894 Cancer 107 2006 489 496
108. D.G. McLeod, P. Iversen, and W.A. See Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 97 2006 247 254
109. M.D. Shelley, S. Kumar, and T. Wilt A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma Cancer Treat Rev 35 2009 9 17